A Western Australian biotech partnership is developing RNA-based therapies to treat type 2 diabetes by directly improving insulin resistance, aiming to move beyond the limitations of popular GLP-1 ...
Biocon has announced that its long-standing partner, Duopharma Biotech Berhad (Duopharma Biotech) via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results